Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

53
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
53
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

93
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
93
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51
Prodrugs01:30

Prodrugs

4.5K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.5K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

59
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
59

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung carcinoids with sustentacular cells and low keratin expression: A common yet under-recognized phenomenon with diagnostic and biological implications.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Venous thromboembolic and bleeding risk in population with obesity hospitalized for an acute medical illness receiving enoxaparin for thromboprophylaxis.

Research and practice in thrombosis and haemostasis·2026
Same author

Scalable diclofenac lauryl ester prodrug nanoparticles: a promising strategy for reducing inflammation associated with intervertebral disc degeneration.

Drug delivery and translational research·2026
Same author

GLP-1 Receptor Agonists and Cardiovascular Events During Androgen Receptor Pathway Inhibitor Therapy.

medRxiv : the preprint server for health sciences·2026
Same author

Publisher Correction: Venous Thromboembolism and Bleeding Risk in a Population with Obesity Hospitalized for Surgery and Receiving Enoxaparin for Thromboprophylaxis.

Obesity surgery·2026
Same author

Venous Thromboembolism and Bleeding Risk in a Population with Obesity Hospitalized for Surgery and Receiving Enoxaparin for Thromboprophylaxis.

Obesity surgery·2026

Related Experiment Video

Updated: Feb 27, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.6K

Single-trigger dual-responsive nanoparticles for controllable and sequential prodrug activation.

Neil M Robertson1, Yang Yang, Irfan Khan

  • 1Department of Chemistry, University at Albany, State University of New York, 1400 Washington Avenue, Albany, New York 12222, USA. myigit@albany.edu mroyzen@albany.edu.

Nanoscale
|July 7, 2017
PubMed
Summary
This summary is machine-generated.

This study introduces a novel nanoparticle drug delivery system that inactivates two drugs until activated by a chemical stimulus. The system releases drugs sequentially, improving therapeutic response in triple-negative breast cancer cells.

More Related Videos

An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation
11:20

An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation

Published on: August 30, 2017

7.9K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

2.0K

Related Experiment Videos

Last Updated: Feb 27, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.6K
An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation
11:20

An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation

Published on: August 30, 2017

7.9K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

2.0K

Area of Science:

  • Nanotechnology
  • Drug Delivery Systems
  • Bioorthogonal Chemistry

Background:

  • Conventional drug delivery often lacks precise control over drug release kinetics.
  • Simultaneous release of multiple synergistic drugs can lead to suboptimal therapeutic outcomes.
  • Developing stimuli-responsive systems for controlled drug activation is crucial for targeted therapies.

Purpose of the Study:

  • To develop a single nanoparticle platform for controlled, time-staggered release of two synergistically acting drugs.
  • To utilize bioorthogonal chemistry for precise control over drug activation and release timing.
  • To investigate the therapeutic efficacy of sequential drug release compared to simultaneous release in triple-negative breast cancer models.

Main Methods:

  • Immobilization of two drugs onto a nanoparticle template, rendering them inactive.
  • Utilizing di-axial and di-equatorial TCO linkers to control 'click-to-release' kinetics.
  • Employing a single small molecule trigger for bioorthogonal activation of drug payloads.
  • Characterization of nanoparticle release kinetics using fluorescent probes and in vitro testing on BT-20 breast cancer cells.

Main Results:

  • Developed a dual-responsive nanoparticle capable of sequential drug release (doxorubicin and PAC-1 prodrugs).
  • Demonstrated controlled release kinetics through bioorthogonal chemistry and specific linker incorporation.
  • Achieved enhanced therapeutic response in vitro against triple-negative breast cancer cells compared to simultaneous release.

Conclusions:

  • The developed nanodrug delivery system enables precise temporal control over the release of multiple drug payloads.
  • Sequential drug release from this platform offers superior therapeutic efficacy over simultaneous release.
  • This approach holds promise for advanced cancer therapies requiring controlled drug administration.